News

Verona Pharma's Upcoming Financial Disclosure and Updates

Verona Pharma's Upcoming Financial Disclosure and Updates

Verona Pharma's Upcoming Financial Disclosure

Verona Pharma plc (NASDAQ: VRNA), a leading biopharmaceutical company, is set to reveal important financial results for the third quarter ended September 30, 2024. The announcement will be made on Monday, November 4, 2024. A pivotal conference call is scheduled for 9:00 a.m. EDT / 2:00 p.m. GMT where executives will discuss the financial outcomes and share key corporate updates.

Joining the Conference Call

Investors and interested participants wishing to join the call can do so by dialing either of the following numbers:

United States Callers

For those located in the United States, please call +1-833-816-1396.

International Callers

International participants can reach out at +1-412-317-0489. Remember to ask for the Verona Pharma call upon connection.

Live Webcast Availability

A live audio webcast of the conference will also be accessible through the Events and Presentations link on the investor section of Verona Pharma's website. Participants will have the chance to access the audio replay of the conference call for a period of 90 days following the event.

Contact Information for Inquiries

For any inquiries regarding the financial results or further information, please reach out to:

Verona Pharma plc

Tel: +1-844-341-9901

Investor Relations

Victoria Stewart, Senior Director of Investor Relations and Communications

Email: IR@veronapharma.com

U.S. Investor Inquiries

Argot Partners
Tel: +1-212-600-1902
Email: verona@argotpartners.com

Media Inquiries

Ten Bridge Communications
Tel: +1-312-523-5016
Email: tbcverona@tenbridgecommunications.com

About Verona Pharma

Verona Pharma is committed to developing innovative therapies aimed at treating chronic respiratory diseases where there is a significant unmet need. Their flagship product, Ohtuvayre™ (ensifentrine), represents a breakthrough as the first inhaled medication that combines bronchodilator and anti-inflammatory properties into a single treatment for COPD. This dual action may extend to other serious respiratory conditions, including chronic bronchiectasis and asthma.

Frequently Asked Questions

When will Verona Pharma announce their Q3 financial results?

Verona Pharma intends to announce their financial results for Q3 on November 4, 2024.

How can I participate in Verona Pharma's conference call?

Participants can join by calling +1-833-816-1396 for U.S. callers or +1-412-317-0489 for international callers.

Where can I find the live webcast of the conference?

The live webcast will be accessible via the Events and Presentations link on Verona Pharma's investor page.

What is Ohtuvayre™?

Ohtuvayre™ (ensifentrine) is Verona Pharma's first product, designed for the maintenance treatment of COPD, combining both bronchodilator and anti-inflammatory effects.

Who can I contact for more information?

You can contact Verona Pharma's investor relations through Victoria Stewart at +1-844-341-9901 or via email at IR@veronapharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hyundai and Texas Children's Boost Child Safety in Houston

Updated Category News Views 6

A Meaningful Partnership for Safer Houston Roads There's a good feeling about corporations genuinely pitching in for community welfare, and Hyundai teaming up with Texas Children's Hospital to boost child passenger safety around Houston is exactly that. Pairing philanthropy with safety is more than just a business move—it's a testament to human decency. With a $25,000...

Continue Reading
Viedoc and Bioforum Unite: Clinical Data Innovation

Updated Category News Views 19

Revamping Clinical Trials with Data Integration It doesn't take a Wall Street wizard to understand that in today's research game, having data is only half the battle—using it effectively is where the rubber meets the road. Enter Viedoc and Bioforum, two names that are well-acquainted with the grind of the clinical research world. These seasoned pros have joined forces,...

Continue Reading
Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

Updated Category News Views 34

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

Continue Reading
Static Media Acquires CarScoops to Boost Auto Reach

Updated Category News Views 24

Static Media's Latest Move in the Automotive Arena The digital media landscape keeps morphing, and Static Media just decided to crank up the gears a notch by snapping up CarScoops.com. For those with an eye on the automotive field, it's the kind of play that could shift the tides. Static Media, already a heavyweight with brands like Jalopnik and SlashGear under its belt,...

Continue Reading
Wabi's $1.25B Valuation: A New Era for AI?

Updated Category News Views 71

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

Continue Reading
Cyclists and Trains: A New Chapter in Urban Travel

Updated Category News Views 23

Rolling Without Engines: LA to SD Picture this: over 75 cyclists and their compact, foldable steeds embarking on a train journey from Los Angeles to the sun-drenched streets of San Diego. In an era where travel is often synonymous with congestion and pollution, this collaboration between Amtrak's Pacific Surfliner and Brompton Bicycle was like a breath of fresh sea air....

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading
Florida 500 Honors Influential Health Leaders of 2026

Updated Category News Views 56

Florida 500: Recognizing Impactful Leaders When it comes to shaking up the healthcare scene in Florida, John Couris and his crew are hardly treading water. Once again, Couris is rubbing elbows with the state's influential set, nabbing a spot on Florida Trend's 2026 "Florida 500" list. If you don't know, that's six years in a row. Those who've walked the grueling paths in...

Continue Reading
Nikon Unveils Game-Changing Zoom Lens for Pros

Updated Category News Views 35

Nikon Raises the Bar with New Pro Zoom Lens Well, Nikon's done it again, folks. They've dropped the NIKKOR Z 120-300mm f/2.8 TC VR S lens, and it looks like they're giving photographers something to drool over. Now, before you start rolling your eyes, this isn't just another shiny gadget. This bad boy is lighter and faster than anything Nikon's thrown at us before, and it...

Continue Reading
InventHelp's BLU MESH: A Breath of Fresh and Bug-Free Air

Updated Category News Views 16

Breathing Fresh Air Without the Buzz Here's a fresh spin on driving with the windows down: avoiding bug invasions. We’ve all experienced it—the unexpected slap on the arm or that annoying buzz in your ear just as you're drifting into a long podcast. Thanks to an inventor from East Stroudsburg, Pa., there's an idea on the table for a vehicular add-on that might just...

Continue Reading

Top 5 Most Recently Viewed Articles

US Treasury Bonds React to Strong Labor Market Signals

Updated Category News Views 151

US Treasury Bonds Experience Decline Amid Labor Market News The recent performance of US Treasury bonds has shown a considerable decrease, reflecting market adjustments to expectations surrounding Federal Reserve interest rate cuts. The decline follows indications of a strong labor market, which have led traders to revise their forecasts for the timing of potential rate...

Continue Reading
Why Estate Planning Belongs in a Long Term Investment Strategy

Updated Category Personal Finance Views 35

Investing often focuses on building wealth, achieving financial independence, and creating greater future security, but protecting what you've already accumulated is equally important. Investors who want to understand how wills, trusts, probate, and other estate planning tools can support the management and transfer of their assets can explore the estate planning services...

Continue Reading
Examining the Executive Authority in CPSC Dismissals

Updated Category News Views 254

NCLA Challenges District Court Ruling on Presidential Authority The New Civil Liberties Alliance (NCLA) has taken a significant legal stand regarding the powers of the President, submitting an amicus curiae brief in a case concerning the removal of Consumer Product Safety Commission (CPSC) commissioners. This case, Boyle v. Trump, seeks to overturn a decision made by a...

Continue Reading
Sanoma Corporation's Recent Share Repurchase Highlights

Updated Category News Views 124

Understanding Sanoma Corporation's Share Buyback Strategy Sanoma Corporation is making headlines with its recent share repurchase program, which reflects a strong commitment to enhancing shareholder value. The initiative is not just a routine financial maneuver; it’s a strategic decision aimed at reinforcing investor confidence and optimizing the company’s capital...

Continue Reading
Loomis Reports Strong Q1 Growth and Operational Efficiency

Updated Category News Views 202

Solid Start to the Year Loomis experienced a promising beginning to the fiscal year, boasting an organic revenue growth of 4.4 percent in the opening quarter. The performance across various segments, including the USA, Europe, and Latin America, showed a remarkable positive trend. Particularly, the International business line stood out, contributing significantly to this...

Continue Reading